Molecular determinants of drug resistance in tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 4, Issue 2 SUPPL. 1, 2000, Pages

  Riska, P F ^a   Jacobs Jr, W R ^b   Alland, D ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; CROSS RESISTANCE; DNA SEQUENCE; GENE MUTATION; GENETIC ANALYSIS; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; GENES, BACTERIAL; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0034092698     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Raviglione M C, Snider D E Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220-226.
2. Maher D, Nunn P. Commentary: making tuberculosis treatment available for all. Bull World Health Organ 1998; 76: 125-126.
3. Mitchison D, Nunn A. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
4. Pablos-Mendez A, Sterling T R, Frieden T R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-1228.
5. Turett G S, Telzak E E, Torian L V, et al. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis 1995; 21: 1238-1244.
6. Pearson M L, Jereb J A, Frieden T R, et al. Nosocomial transmission of multi-drug resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med 1992; 117: 191-196.
7. Fujiwara P, Cook S V, Rutherford C M, et al. A continuing sur vey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157: 531-536.
8. Pablos Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998; 338: 1641-1649.
9. Musser J M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microb Rev 1995; 8: 496-514.
10. Warren R M, Shah S S, Alland D. Multiple drug resistance: a world-wide threat. In: Malin A, McAdam K P W J, eds. Baillère's clinical infectious diseases, international practice and research. Mycobacterial diseases part I: clinical frontiers. London: Baillière Tindall, 1997; 4: 77-96.
11. Yew W W, Chau C H. Drug resistant tuberculosis in the 1990s. Eur Respir J 1995; 8: 1184-1192.
12. Cole S T, Telenti A. Drug resistance in Mycobacterium tuberculosis. Eur Respir J 1995; 20 (Suppl): 701s-713s.
13. Blanchard J S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Ann Rev Biochem 1996; 65: 215-239.
14. Telenti A. Genetics of drug resistance in tuberculosis. Clin Chest Med 1997; 18: 55-64.
15. Rattan A, Kalia A, Ahmad N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 1998; 4: 195-209.
16. Sreevatsan S, Pan X, Stockbauer K E, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination. Proc Natl Acad Sci USA 1997; 94: 9869-9874.
17. Noordhoek G T, Kolk A H, Bjune G, et al. Sensitivity and spec ificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 1994; 32: 277-284.
18. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T. Direct, automated detection of rifampin resistant Mycobacterium tuberculosis by polymerase chain reaction and single strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993; 37: 2054-2058.
19. Ohno H, Koga H, Kuroita T, et al. Rapid prediction of rifampin susceptibility of Mycrobacterium tuberculosis. Am J Respir Crit Care Med 1997; 155: 2057-2063.
20. Rossau R, Traore H, De Beenhouwer H, et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculous complex and its resistance to rifampin. Antimicrob Agents Chemother 1997; 41: 2093-2098.
21. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35: 719-723.
22. Heym B, Honore N, Truffot-Pernot C, et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994; 344: 293-298.
23. Morris S, Bai G H, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995; 171: 954-960.
24. Nachamkin I, Kang C, Weinstein M P. Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin Infect Dis 1997; 24: 894-900.
25. Williams D L, Waguespack C, Eisenach K, et al. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994; 38: 2380-2386.
26. Felmlee T A, Liu Q, Whelen A C, Williams D, Sommer S S, Persing D H. Genorypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting. J Clin Microbiol 1995; 33: 1617-1623.
27. Piatek A S, Tyagi S, Pol A C, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nature Biotechnol 1998; 16: 359-363.
28. Gingeras T R, Ghandour G, Wang E, et al. Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Genome Res 1998; 8: 435-448.
29. Rouse D A, Morris S L. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect Immun 1995; 63: 1427-1433.
30. Ad Hoc Committee on the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crir Care Med 1994; 149: 1359-1374.
31. Koch Weser D, Ebert R H, Barclay W R, Lee V S. Studies on the metabolic significance of acid fastness of tubercle bacilli. J Lab Clin Med 1953; 42: 828-829.
32. Takayama K, Schnoes H K, Armstrong E L, Boyle R W Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J Lipid Res 1975; 16: 308-317.
33. Middlebrook G. INH resistance and catalase activity of the tubercle bacilli. Am Rev Tuberc 1954; 69: 471-172.
34. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
35. Winder F. The antibacterial action of streptomycin, isoniazid, and PAS. In: Barry V C, ed. Chemotherapy of tuberculosis. London: Butterworths, 1964; 111-149.
36. Lefford M J. The ethionamide sensitivity of British pre-treatment strains of Mycobacterium tuberculosis. Tubercle 1966; 47: 198-206.
37. Bancrjee A, Duhnau E, Quemard A, et al. inbA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230.
38. Mdluli K, Slayden R A, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280: 1607-1610.
39. Deretic V, Philipp W, Dhandayuthapani S, et al. Mycobacterium tuberculosis is a natural mutant with an inactivated oxi-dative-stress regulatory gene: implications for sensitivity to isoniazid. Mol Microbiol 1995; 17: 889-900.
40. Kelley C L, Rouse D A, Morris S L. Analysis of abpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 2057-2058.
41. Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser J M. Analysis of the oxyR-abpC region in isoniazid-resistant and susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997; 41: 600-606.
42. Musser J M, Kapur V, Williams D L, Kreiswirth B N, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (katC) and inbA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996; 173: 196-202.
43. Piatek A S, Telenti A, Murray M R, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother (in press).
44. Dessen A, Quemard A, Blanchard J S, Jacobs W R Jr, Sacchettini J C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995; 267; 1638-1641.
45. Ristow M, Mohlig M, Rifai M, Schatz H, Feldmann K, Pfeiffer A. New isoniazid/ethionamide resistance gene mutation and screening for multidrug resistant Mycobacterium tuberculosis strains. Lancet 1995; 346: 502-503.
46. Sacchettini J C, Blanchard J S. The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol 1996; 147: 36-43.
47. Wilson T M, Collins D M. abpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996; 19: 1025-1034.
48. Rouse D A, DeVito JA, Li Z, Byer U, Morris S L. Site directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase peroxidase activities and isoniazid resistance. Mol Microbiol 1996; 22: 583-592.
49. Miesel L, Weisbrod T R, Marcinkeviciene J, Bittman R, Jacobs W R Jr. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol 1998; 180: 2459-2467.
50. Middlebrook G, Cohn M L. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 1953; 118: 297-299.
51. Ridzon R, Whitney C G, McKenna M T, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-1884.
52. Miller L P, Crawford J T, Shinnick T M. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 805-811.
53. Kapur V, Li I. I., Iordanescu S, et al. Characterization by auto mated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerasc beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32: 1095-1098.
54. Taniguchi H, Aramaki H, Nikaido Y, et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett 1996; 144: 103-108.
55. Kim B J, Kim S Y, Park B H, et al. Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR singlestrand conformation polymorphism analysis for rifampin susceptibility testing. J Clin Microbiol 1997; 35: 492-494.
56. Riska P F, Su Y, Bardarov S, et al. Rapid film-based determination of antibiotic susceptibilities of Mycobacterium tuberculosis strains by using a Iuciferase reporter phage and the Bronx Box. J Clin Microbiol 1999; 37: 1144-1149.
57. Williams D L, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853-1857.
58. Yang B, Koga H, Ohno H, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-628.
59. Heifets L B. Drug susceptibility in the chemotherapy of mycobactenal infections. Boca Raton: CRC Press, 1991.
60. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2: 662-667.
61. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-543.
62. Sreevatsan S, Pan X, Zhang Y, Kreiswirth B N, Musser J M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41: 636-640.
63. Telenti A, Philipp W J, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997; 3: 567-570.
64. Belanger A E, Besra G S, Ford M K, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996; 93: 11919-11924.
65. Sreevatsan S, Stockbauer K E, Pan X, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997; 41: 1677-1681.
66. Meier A, Sander P, Schaper K J, Scholz M, Bottger E C. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2452-2454.
67. Sreevatsan S, Pan X, Stockbauer K E, Williams D L, Kreiswirth B N, Musser J M. Characterization of rpsL and rrs mutations in streptomycin resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996; 40: 1024-1026.
68. Alangaden G J, Kreiswirth B N, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterum tuberculosis. Antimicrob Agents Chemother 1998; 42: 1295-1297.
69. Suzuki Y, Katsukawa C, Tamaru A, et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying muta tions in the 16S rRNA gene. J Clin Microbiol 1998; 36: 1220-1225.
70. Hong Kong Chest Service/ British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuber culosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67.
71. Takiff H E, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobaclerium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
72. Xu C, Kreiswirth B N, Sreevatsan S, Musser J M, Drlica K. Flu oroquinolone resistance associated with specific gyrase muta tions in clinical isolates of multidrug-resistant Mycobacterinm tuberculosis. J Infect Dis 1996; 174: 1127-1130.
73. Takiff H E, Cimino M, Musso M C, et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegniatis. Proc Natl Acad Sci USA 1996; 93: 362-366.